Safety and Efficacy of Infliximab in Palmoplantar Psoriasis

• Sponsor: Innovaderm Research Inc. (Other)
• Overall Status: Completed
• CT.gov ID: NCT00629772
• Collaborator: Schering-Plough (Industry)
• Enrollment: 24
• Locations: 5
• Arms: 2
• Duration (Months): 28
• Patients Per Site: 4.8
• Patients Per Site Per Month: 0.2

Study Details

Study Description

Brief Summary

Palmoplantar psoriasis is a variant of psoriasis affecting palms and soles. It is one of the most debilitating variants of psoriasis which very often interferes with daily activities and with the ability to work. This type of psoriasis is very difficult to treat as topicals have difficulty penetrating the thick epidermis of palms and soles and are therefore not very effective. The response to standard agents (methotrexate, cyclosporine and acitretin) is also usually limited. A number of these patients have very severe hand and feet disease with mild to no involvement elsewhere on the body.

Given the efficacy of infliximab in psoriasis, the purpose of this study is to evaluate if infliximab is safe and if it will improve severity and quality of life in patients with palmoplantar psoriasis, a debilitating variant of psoriasis.

Condition or Disease	Intervention/Treatment	Phase
Palmoplantar Psoriasis	Drug: Placebo; Drug: Infliximab	Phase 3

Detailed Description

A total of 24 patients with non-pustular palmoplantar psoriasis affecting at least 10% of the combined palms and soles area and with a modified palmoplantar pustulosis area severity index (m-PPPASI) of at least 8 will be recruited. Patients will be randomized (1:1) to receive either infliximab 5 mg/kg or placebo (normal saline) on weeks 0, 2 and 6. Patients assigned to placebo during the first 3 infusions will receive infliximab 5 mg/kg at weeks 14, 16 and 20 and placebo again at week 22 while patients who were assigned to receive infliximab during the first 3 infusions will receive infliximab at week 14 and placebo at week 16 and week 20 as well as infliximab for the last infusion at week 22. The primary endpoint will be at week 14. Patients will come back to the clinic at week 26 for a final efficacy and safety assessment.

Efficacy will be evaluated by assessing psoriasis plaque severity on palms and soles (physician's global assessment PGA), percentage of palms and soles area affected by psoriasis (palmoplantar surface area - PPSA) as well as m-PPPASI (modified palmoplantar pustulosis area and severity index). Quality of life will be evaluated at every visit by performing the dermatology life quality index DLQI. Safety will be evaluated by repeating chemistry and haematology laboratories at regular visits as well as by physical examinations and assessment of adverse events.

Study Design

• Study Type: Interventional
• Actual Enrollment: 24 participants
• Allocation: Randomized
• Intervention Model: Crossover Assignment
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: A Double-Blind Study on the Safety and Efficacy of Infliximab in Palmoplantar Psoriasis
• Study Start Date: Mar 1, 2007
• Actual Primary Completion Date: Feb 1, 2009
• Actual Study Completion Date: Jul 1, 2009

Arms and Interventions

Arm	Intervention/Treatment
Placebo Comparator: Placebo then infliximab Placebo at weeks 0, 2, 6 during the first intervention period and infliximab 5mg/kg at weeks 14, 16 and 20 during second intervention period.	Drug: Placebo; Patients receive placebo on weeks 0, 2 and 6. They receive infliximab 5mg/kg at weeks 14, 16 and 20.; Other Names: Saline ; Drug: Infliximab; Patients in infliximab group receive infliximab 5mg/kg at weeks 0, 2, 6, 14 and 22. Patients in placebo then infliximab group receive placebo at weeks 0, 2, 6, then receive infliximab at weeks 14, 16 and 20.; Other Names: Remicade
Active Comparator: Infliximab Infliximab 5mg/kg at weeks 0, 2, 6, 14 and 22.	Drug: Infliximab; Patients in infliximab group receive infliximab 5mg/kg at weeks 0, 2, 6, 14 and 22. Patients in placebo then infliximab group receive placebo at weeks 0, 2, 6, then receive infliximab at weeks 14, 16 and 20.; Other Names: Remicade

Outcome Measures

Primary Outcome Measures

1. 75% Improvement in Modified Palmoplantar Pustulosis Area and Severity Index (m-PPPASI) From Day 0 [14 weeks]

   Efficacy by comparing the number of patients reaching a 75% improvement in m-PPPASI (m-PPPASI 75) m-PPPASI = (E + I + D)Area X 0.2 (R palm) + (E + I + D) Area X 0.2 (L palm) + (E + I + D) Area X 0.3 (R sole) + (E + I + D) Area X 0.3 (L sole). Erythema, induration and desquamation are evaluated on a scale of 0 to 4 while area is evaluated on a scale of 0 to 6. The m-PPPASI score can vary from 0 (absence of disease) to 72 (most severe palmoplantar psoriasis possible).

Secondary Outcome Measures

1. Number of Adverse Events at Week 14 [14 weeks]

   Safety of infliximab administered for 14 weeks in patients who received by comparing adverse events

2. Mean Dermatology Life Quality Index (DLQI) at Week 14 [14 weeks]

   Impact on quality of life with the Dermatology Life Quality Index (DLQI) The aim of the questionnaire is to measure how much a patient's skin problem has affected their life over the previous week. 0-1 = no effect at all on patient's life 2-5 = small effect on patient's life 6-10 = moderate effect on patient's life 11-20 = very large effect on patient's life 21-30 = extremely large effect on patient's life

3. Mean Percent Palmoplantar Psoriasis Surface Area (PPSA) at Week 14 [14 weeks]

   Efficacy by comparing the mean percent PPSA. The surface affected by psoriasis on palms and soles is estimated on the day of the visit as a percentage of the total surface of palms and soles affected by psoriasis. Each palm represents 20% and each sole 30%. As a rule of thumb half a palm equals 10% of the total surface area of palm and soles. A sole completely covered with psoriasis would have a PPSA of 30% (if the other sole and the palms are unaffected) while a palm completely covered with psoriasis would have a PPSA of 20% (if the other palm and the soles are unaffected).

4. Mean Physician's Global Assessment (PGA) at Week 14 [14 weeks]

   Efficacy by comparing the mean Physician's Global Assessment(PGA). 0 = clear. 1 = almost clear. 2 = Mild. 3 = Moderate. 4 = Severe. 5 = Very severe.

5. Mean Percent Improvement in Modified Palmoplantar Pustulosis Area and Severity Index (m-PPPASI) at Week 26 [Baseline, 26 weeks]

   Efficacy of infliximab administered for 22 weeks in patients who received infliximab at Day 0 by evaluating the improvement over time in modified m-PPPASI from Day 0 to Week 26. m-PPPASI = (E + I + D)Area X 0.2 (R palm) + (E + I + D) Area X 0.2 (L palm) + (E + I + D) Area X 0.3 (R sole) + (E + I + D) Area X 0.3 (L sole). Erythema, induration and desquamation are evaluated on a scale of 0 to 4 while area is evaluated on a scale of 0 to 6. The m-PPPASI score can vary from 0 (absence of disease) to 72 (most severe palmoplantar psoriasis possible).

6. Mean Percent Improvement in Dermatology Life Quality Index (DLQI) at Week 26 [Baseline, 26 weeks]

   Efficacy of infliximab administered for 22 weeks in patients who received infliximab at Day 0 by evaluating the improvement over time in dermatology life quality index (DLQI) from Day 0 to Week 26. Impact on quality of life with the DLQI. The aim of the questionnaire is to measure how much a patient's skin problem has affected their life over the previous week. 0-1 = no effect at all on patient's life 2-5 = small effect on patient's life 6-10 = moderate effect on patient's life 11-20 = very large effect on patient's life 21-30 = extremely large effect on patient's life

7. Mean Percent Improvement in Physician's Global Assessment (PGA) at Week 26 [Baseline, 26 weeks]

   Efficacy of infliximab administered for 22 weeks in patients who received infliximab at Day 0 by evaluating the improvement over time in Physician's Global Assessment (PGA) from Day 0 to Week 26. 0 = clear 1 = almost clear 2 = Mild 3 = Moderate 4 = Severe 5 = Very severe

8. Mean Percent Improvement in Palmoplantar Psoriasis Surface Area (PPSA) at Week 26 [Baseline, 26 weeks]

   Efficacy of infliximab administered for 22 weeks in patients who received infliximab at Day 0 by evaluating the improvement over time in percent PPSA from Day 0 to Week 26. The surface affected by psoriasis on palms and soles is estimated on the day of the visit as a percentage of the total surface of palms and soles affected by psoriasis. Each palm represents 20% and each sole 30%. As a rule of thumb half a palm equals 10% of the total surface area of palm and soles.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• Patient is 18 years of age or older.

• Patient has a history of palmoplantar psoriasis for at least 6 months.

• Patient has a m-PPPASI of at least 8 with at least 10% of the total surface of palms and soles affected with psoriasis at baseline

• Patients who failed either 4 weeks (or more) of treatment with a potent or superpotent topical corticosteroid, methotrexate, acitretin, cyclosporine, efalizumab, etanercept or alefacept for the treatment of palmoplantar psoriasis. Patients with a positive PPD who accept TB prophylaxis, will need to have failed 4 weeks (or more) of treatment with methotrexate, acitretin, cyclosporine, efalizumab, etanercept, alefacept or any other systemic therapies for the treatment of palmoplantar psoriasis.

• Patient with a history and/or the presence of typical plaque psoriasis outside palms and soles

• Female patient is either not of childbearing potential or is of childbearing potential and practicing an acceptable contraception

• Female patients of childbearing potential must have a negative serum pregnancy test at the Screening visit.

• Patient is judged to be in good general health as determined by the principal investigator based upon the results of medical history, laboratory profile, and physical examination performed at Screening

• The investigator evaluates that the benefit / risk ratio is acceptable for the patient.

• Patients must be able and willing to provide written informed consent and comply with the requirements of this study protocol.

• Negative PPD

• Patients with a positive PPD may be eligible if they initiate TB prophylaxis before the first injection of infliximab

Exclusion Criteria:

• Patient has a history of pustules on palms and/or soles or currently has evidence of pustules on palms and/or soles.

• Patient with Chest X Ray findings positive or suspicious for active tuberculosis.

• Patient has had opportunistic infections.

• Patient has had active TB or recent close contact with an individual with active TB.

• Patient has had a serious infection, has been hospitalized for an infection, or has been treated with intravenous (IV) antibiotics for an infection within 2 months prior to Day 0.

• Patient has had a chronic or recurrent infectious disease including hepatitis B or hepatitis C.

• Patient has a known malignancy or history of malignancy within 5-year period prior to screening (with the exception of squamous or basal cell carcinoma of the skin that has been completely excised without evidence of recurrence).

• Patient has a history of lymphoproliferative disease, has multiple sclerosis, or other central demyelinating disorder, or congestive heart failure.

• Patient has elevated aspartate aminotransferase or alanine aminotransferase levels more than twice the upper limit of normal at screening.

• Patient has received live vaccination within 3 months of randomization or plans to receive live vaccination during the study or within 3 months after the last infusion.

• Patient is pregnant, breastfeeding, or planning pregnancy (both men and women) during the trial or within the 6-month period thereafter.

• Patient has a history of an allergic reaction to infliximab or any constituent of study drug.

• Patient who has used any topical treatment for psoriasis (except non-medicated emollients) in the last 2 weeks before Day 0 with the exception of hydrocortisone and desonide for the face, groin (including genitals) and inframammary areas as well as shampoos containing tar, salicylic acid or zinc pyrithione

• Patient who has used UVB phototherapy or excessive sun exposure less than 14 days before Day 0.

• Patient has used any non-biological systemic therapy for the treatment of psoriasis (including PUVA therapy), systemic steroids or systemic immunosuppressants less than 28 days before Day 0. Investigational non-biologics agents must be discontinued at least 28 days or 5 half-lives prior to Day 0 (whichever is longer).

• Patient is currently participating in a clinical trial with an experimental drug or device.

• Patient who has used any biological therapy for the treatment of psoriasis less than 90 days before day 0.

• Patient is taking or requires oral or injectable corticosteroids during the study. Inhaled corticosteroids for stable medical conditions are allowed. Patients who have used oral or injectable corticosteroids less than 28 days before Day 0 are excluded.

• Patient has a poorly controlled medical condition which, in the opinion of the investigator, would put the patient at risk if the patient participated in the study.

• Patient currently uses or plans to use anti-retroviral therapy at any time during the study.

• Patient is known to have immune deficiency or is immunocompromised.

• Patient is known to be infected with the human immunodeficiency virus, hepatitis B or hepatitis C virus.

• Patient has current signs or symptoms or has a history of systemic lupus erythematosus.

• Patient has a history of clinically significant drug or alcohol abuse in the last year.

• Patient has erythrodermic psoriasis, generalized or localized pustular psoriasis, medication-induced or medication-exacerbated psoriasis.

• Patients with a positive PPD who accept TB prophylaxis must not have any pre-existing liver disease.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	The Guenther Dermatology Research Center	London	Ontario	Canada	N6A 3H7
2	Lynderm Research Inc.	Markham	Ontario	Canada	L3P 1A8
3	Innovaderm Research Laval	Laval	Quebec	Canada	H7S 2C6
4	Innovaderm Research	Montreal	Quebec	Canada	H2K 4L5
5	Centre de recherche dermatologique du Québec Métropolitain	Quebec		Canada	G1V 4X7

Sponsors and Collaborators

• Innovaderm Research Inc.
• Schering-Plough

Investigators

• Principal Investigator: Robert Bissonnette, MD, Innovaderm Research

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Innovaderm Research Inc.
• ClinicalTrials.gov Identifier: NCT00629772
• Other Study ID Numbers: Inno-6003; P-05121
• First Posted: Mar 6, 2008
• Last Update Posted: Sep 9, 2011
• Last Verified: Sep 1, 2011

• Keywords provided by Innovaderm Research Inc.: Palmoplantar psoriasis; Infliximab
• Additional relevant MeSH terms: Psoriasis; Infliximab

Study Results

Participant Flow

Arm/Group Title	Placebo Then Infliximab	Infliximab
Arm/Group Description	Placebo at weeks 0, 2, 8 during the first intervention period and infliximab 5mg/kg at weeks 14, 16 and 20 during second intervention period.	Infliximab 5mg/kg at weeks 0, 2, 6, 14 and 22.
Period Title: First Intervention - Day 0 - Week 14
STARTED	12	12
COMPLETED	12	12
NOT COMPLETED	0	0
Period Title: First Intervention - Day 0 - Week 14
STARTED	12	12
COMPLETED	11	10
NOT COMPLETED	1	2

Baseline Characteristics

Arm/Group Title	Placebo Then Infliximab	Infliximab	Total
Arm/Group Description	Placebo at weeks 0, 2, 8 during the first intervention period and infliximab 5mg/kg at weeks 14, 16 and 20 during second intervention period.	Infliximab 5mg/kg at weeks 0, 2, 6, 14 and 22.	Total of all reporting groups
Overall Participants	12	12	24
Age (Count of Participants)
<=18 years	0 0%	0 0%	0 0%
Between 18 and 65 years	11 91.7%	9 75%	20 83.3%
>=65 years	1 8.3%	3 25%	4 16.7%
Age (years) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [years]	49.92 (14.74)	57.83 (12.42)	53.87 (13.92)
Sex: Female, Male (Count of Participants)
Female	8 66.7%	7 58.3%	15 62.5%
Male	4 33.3%	5 41.7%	9 37.5%
Region of Enrollment (participants) [Number]
Canada	12 100%	12 100%	24 100%
Modified Palmoplantar Pustulosis Area and Severity Index (m-PPPASI) (Units on a scale) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [Units on a scale]	26.7 (12.4)	24.1 (11.4)	25.4 (11.7)
Dermatology Life Quality Index (DLQI) (Units on a scale) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [Units on a scale]	11.9 (6.9)	9.8 (4.4)	10.8 (5.8)
Physician's Global Assessment (PGA) (Units on as scale) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [Units on as scale]	3.8 (0.6)	3.5 (0.7)	3.7 (0.6)
Palmoplantar Psoriasis Surface Area PPSA (Percentage of affected area) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [Percentage of affected area]	40.4 (21.6)	37.1 (21.0)	38.8 (20.9)

Outcome Measures

1. Primary Outcome

Title	75% Improvement in Modified Palmoplantar Pustulosis Area and Severity Index (m-PPPASI) From Day 0
Description	Efficacy by comparing the number of patients reaching a 75% improvement in m-PPPASI (m-PPPASI 75) m-PPPASI = (E + I + D)Area X 0.2 (R palm) + (E + I + D) Area X 0.2 (L palm) + (E + I + D) Area X 0.3 (R sole) + (E + I + D) Area X 0.3 (L sole). Erythema, induration and desquamation are evaluated on a scale of 0 to 4 while area is evaluated on a scale of 0 to 6. The m-PPPASI score can vary from 0 (absence of disease) to 72 (most severe palmoplantar psoriasis possible).
Time Frame	14 weeks

Outcome Measure Data

Analysis Population Description

The analysis was performed on the intent to treat (ITT) population. Nonresponder imputation (NRI) was used for patients who withdrew before the end of the study. They were treated as nonresponders from the point of withdrawal onward.

Arm/Group Title	Placebo Then Infliximab	Infliximab
Arm/Group Description	Placebo at weeks 0, 2, 8 during the first intervention period and infliximab 5mg/kg at weeks 14, 16 and 20 during second intervention period.	Infliximab 5mg/kg at weeks 0, 2, 6, 14 and 22.
Measure Participants	12	12
Number [Participants]	1 8.3%	4 33.3%

2. Secondary Outcome

Title	Number of Adverse Events at Week 14
Description	Safety of infliximab administered for 14 weeks in patients who received by comparing adverse events
Time Frame	14 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Placebo Then Infliximab	Infliximab
Arm/Group Description	Placebo at weeks 0, 2, 8 during the first intervention period and infliximab 5mg/kg at weeks 14, 16 and 20 during second intervention period.	Infliximab 5mg/kg at weeks 0, 2, 6, 14 and 22.
Measure Participants	12	12
Number [Adverse Events]	20	32

3. Secondary Outcome

Title	Mean Dermatology Life Quality Index (DLQI) at Week 14
Description	Impact on quality of life with the Dermatology Life Quality Index (DLQI) The aim of the questionnaire is to measure how much a patient's skin problem has affected their life over the previous week. 0-1 = no effect at all on patient's life 2-5 = small effect on patient's life 6-10 = moderate effect on patient's life 11-20 = very large effect on patient's life 21-30 = extremely large effect on patient's life
Time Frame	14 weeks

Outcome Measure Data

Analysis Population Description

The analysis was performed on the intent to treat (ITT) population and the imputation technique was last observation carried forward (LOCF).

Arm/Group Title	Placebo Then Infliximab	Infliximab
Arm/Group Description	Placebo at weeks 0, 2, 8 during the first intervention period and infliximab 5mg/kg at weeks 14, 16 and 20 during second intervention period.	Infliximab 5mg/kg at weeks 0, 2, 6, 14 and 22.
Measure Participants	12	12
Mean (Standard Deviation) [Units on a scale]	9.25 (7.23)	4.50 (5.98)

4. Secondary Outcome

Title	Mean Percent Palmoplantar Psoriasis Surface Area (PPSA) at Week 14
Description	Efficacy by comparing the mean percent PPSA. The surface affected by psoriasis on palms and soles is estimated on the day of the visit as a percentage of the total surface of palms and soles affected by psoriasis. Each palm represents 20% and each sole 30%. As a rule of thumb half a palm equals 10% of the total surface area of palm and soles. A sole completely covered with psoriasis would have a PPSA of 30% (if the other sole and the palms are unaffected) while a palm completely covered with psoriasis would have a PPSA of 20% (if the other palm and the soles are unaffected).
Time Frame	14 weeks

Outcome Measure Data

Analysis Population Description

The analysis was performed on the intent to treat (ITT) population and the imputation technique was last observation carried forward (LOCF).

Arm/Group Title	Placebo Then Infliximab	Infliximab
Arm/Group Description	Placebo at weeks 0, 2, 8 during the first intervention period and infliximab 5mg/kg at weeks 14, 16 and 20 during second intervention period.	Infliximab 5mg/kg at weeks 0, 2, 6, 14 and 22.
Measure Participants	12	12
Mean (Standard Deviation) [Percentage of affected area]	38.58 (20.6)	17.23 (15.75)

5. Secondary Outcome

Title	Mean Physician's Global Assessment (PGA) at Week 14
Description	Efficacy by comparing the mean Physician's Global Assessment(PGA). 0 = clear. 1 = almost clear. 2 = Mild. 3 = Moderate. 4 = Severe. 5 = Very severe.
Time Frame	14 weeks

Outcome Measure Data

Analysis Population Description

The analysis was performed on the intent to treat (ITT) population and the imputation technique was last observation carried forward (LOCF).

Arm/Group Title	Placebo Then Infliximab	Infliximab
Arm/Group Description	Placebo at weeks 0, 2, 8 during the first intervention period and infliximab 5mg/kg at weeks 14, 16 and 20 during second intervention period.	Infliximab 5mg/kg at weeks 0, 2, 6, 14 and 22.
Measure Participants	12	12
Mean (Standard Deviation) [Units on a scale]	3.33 (1.37)	2 (0.95)

6. Secondary Outcome

Title	Mean Percent Improvement in Modified Palmoplantar Pustulosis Area and Severity Index (m-PPPASI) at Week 26
Description	Efficacy of infliximab administered for 22 weeks in patients who received infliximab at Day 0 by evaluating the improvement over time in modified m-PPPASI from Day 0 to Week 26. m-PPPASI = (E + I + D)Area X 0.2 (R palm) + (E + I + D) Area X 0.2 (L palm) + (E + I + D) Area X 0.3 (R sole) + (E + I + D) Area X 0.3 (L sole). Erythema, induration and desquamation are evaluated on a scale of 0 to 4 while area is evaluated on a scale of 0 to 6. The m-PPPASI score can vary from 0 (absence of disease) to 72 (most severe palmoplantar psoriasis possible).
Time Frame	Baseline, 26 weeks

Outcome Measure Data

Analysis Population Description

The analysis was performed on the intent to treat (ITT) population and the imputation technique was last observation carried forward (LOCF).

Arm/Group Title	Infliximab
Arm/Group Description	Infliximab 5mg/kg at weeks 0, 2, 6, 14 and 22.
Measure Participants	12
Mean (Standard Deviation) [Percent improvement]	71.81 (31.59)

7. Secondary Outcome

Title	Mean Percent Improvement in Dermatology Life Quality Index (DLQI) at Week 26
Description	Efficacy of infliximab administered for 22 weeks in patients who received infliximab at Day 0 by evaluating the improvement over time in dermatology life quality index (DLQI) from Day 0 to Week 26. Impact on quality of life with the DLQI. The aim of the questionnaire is to measure how much a patient's skin problem has affected their life over the previous week. 0-1 = no effect at all on patient's life 2-5 = small effect on patient's life 6-10 = moderate effect on patient's life 11-20 = very large effect on patient's life 21-30 = extremely large effect on patient's life
Time Frame	Baseline, 26 weeks

Outcome Measure Data

Analysis Population Description

The analysis was performed on the intent to treat (ITT) population and the imputation technique was last observation carried forward (LOCF).

Arm/Group Title	Infliximab
Arm/Group Description	Infliximab 5mg/kg at weeks 0, 2, 6, 14 and 22.
Measure Participants	12
Mean (Standard Deviation) [Percent improvement]	63.45 (30.29)

8. Secondary Outcome

Title	Mean Percent Improvement in Physician's Global Assessment (PGA) at Week 26
Description	Efficacy of infliximab administered for 22 weeks in patients who received infliximab at Day 0 by evaluating the improvement over time in Physician's Global Assessment (PGA) from Day 0 to Week 26. 0 = clear 1 = almost clear 2 = Mild 3 = Moderate 4 = Severe 5 = Very severe
Time Frame	Baseline, 26 weeks

Outcome Measure Data

Analysis Population Description

The analysis was performed on the intent to treat (ITT) population and the imputation technique was last observation carried forward (LOCF).

Arm/Group Title	Infliximab
Arm/Group Description	Infliximab 5mg/kg at weeks 0, 2, 6, 14 and 22.
Measure Participants	12
Mean (Standard Deviation) [Percent improvement]	47.92 (41.76)

9. Secondary Outcome

Title	Mean Percent Improvement in Palmoplantar Psoriasis Surface Area (PPSA) at Week 26
Description	Efficacy of infliximab administered for 22 weeks in patients who received infliximab at Day 0 by evaluating the improvement over time in percent PPSA from Day 0 to Week 26. The surface affected by psoriasis on palms and soles is estimated on the day of the visit as a percentage of the total surface of palms and soles affected by psoriasis. Each palm represents 20% and each sole 30%. As a rule of thumb half a palm equals 10% of the total surface area of palm and soles.
Time Frame	Baseline, 26 weeks

Outcome Measure Data

Analysis Population Description

The analysis was performed on the intent to treat (ITT) population and the imputation technique was last observation carried forward (LOCF).

Arm/Group Title	Infliximab
Arm/Group Description	Infliximab 5mg/kg at weeks 0, 2, 6, 14 and 22.
Measure Participants	12
Mean (Standard Deviation) [Percent improvement]	65.91 (38.91)

Adverse Events

Time Frame	Adverse events were collected for all patients after the informed consent form was signed until the end of the study at week 26.
Adverse Event Reporting Description	Patients randomized to placebo then infliximab did not receive infliximab prior to week 14.
Arm/Group Title	Infliximab		Placebo Then Infliximab
Arm/Group Description	Infliximab 5mg/kg at weeks 0, 2, 6, 14 and 22 throughout the entire study.		Placebo at weeks 0, 2, 8 during the first intervention period and infliximab 5mg/kg at weeks 14, 16 and 20 during second intervention period.
All Cause Mortality
	Infliximab		Placebo Then Infliximab
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	/ (NaN)		/ (NaN)
Serious Adverse Events
	Infliximab		Placebo Then Infliximab
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	2/12 (16.7%)		1/12 (8.3%)
Hepatobiliary disorders
Hepatitis	1/12 (8.3%)	1	0/12 (0%)	0
Infections and infestations
Cellulitis Right Cheek	0/12 (0%)	0	1/12 (8.3%)	1
Musculoskeletal and connective tissue disorders
Sternum Fracture	1/12 (8.3%)	1	0/12 (0%)	0
Other (Not Including Serious) Adverse Events
	Infliximab		Placebo Then Infliximab
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	11/12 (91.7%)		10/12 (83.3%)
Gastrointestinal disorders
Abdominal pain	1/12 (8.3%)	3	0/12 (0%)	0
Nausea	1/12 (8.3%)	1	1/12 (8.3%)	1
Oesophageal reflux with pyrosis	1/12 (8.3%)	1	0/12 (0%)	0
Vomiting and Diarrhea	0/12 (0%)	0	1/12 (8.3%)	1
General disorders
Fatigue	2/12 (16.7%)	3	1/12 (8.3%)	1
Hair Loss	0/12 (0%)	0	1/12 (8.3%)	1
Swelling left arm	0/12 (0%)	0	1/12 (8.3%)	1
Infections and infestations
Bronchitis	0/12 (0%)	0	1/12 (8.3%)	2
Cellulitis Right Elbow	1/12 (8.3%)	1	0/12 (0%)	0
Common cold	3/12 (25%)	3	3/12 (25%)	4
Cystitis	1/12 (8.3%)	1	0/12 (0%)	0
Influenza	1/12 (8.3%)	1	0/12 (0%)	0
Paronychia	1/12 (8.3%)	1	0/12 (0%)	0
Urinary tract infection	0/12 (0%)	0	1/12 (8.3%)	1
Vaginal infection	0/12 (0%)	0	1/12 (8.3%)	1
Injury, poisoning and procedural complications
Burn right arm	1/12 (8.3%)	1	0/12 (0%)	0
Costal ribs fracture	1/12 (8.3%)	1	0/12 (0%)	0
Tibia fracture	1/12 (8.3%)	1	0/12 (0%)	0
Musculoskeletal and connective tissue disorders
Back pain	0/12 (0%)	0	3/12 (25%)	4
Cervical pain	1/12 (8.3%)	1	0/12 (0%)	0
Ganglion	0/12 (0%)	0	1/12 (8.3%)	1
Joint pain in hand	2/12 (16.7%)	2	0/12 (0%)	0
Knee pain	1/12 (8.3%)	2	0/12 (0%)	0
Lower legs pain	0/12 (0%)	0	1/12 (8.3%)	1
Pain in foot	1/12 (8.3%)	1	0/12 (0%)	0
Pain left shoulder	0/12 (0%)	0	1/12 (8.3%)	1
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Inflammed Seborrheic Keratosis	1/12 (8.3%)	1	0/12 (0%)	0
Nervous system disorders
Burning sensation to feet	1/12 (8.3%)	3	0/12 (0%)	0
Dizziness	1/12 (8.3%)	1	0/12 (0%)	0
Headache	1/12 (8.3%)	1	1/12 (8.3%)	1
Somnolence	1/12 (8.3%)	1	0/12 (0%)	0
Vagal reaction	1/12 (8.3%)	1	0/12 (0%)	0
Respiratory, thoracic and mediastinal disorders
Shortness of breath	1/12 (8.3%)	3	0/12 (0%)	0
Worsening of asthma	0/12 (0%)	0	1/12 (8.3%)	1
Skin and subcutaneous tissue disorders
Dermatitis	1/12 (8.3%)	1	1/12 (8.3%)	1
Erythema right forearm and both thighs	1/12 (8.3%)	1	0/12 (0%)	0
Feet Oedema	1/12 (8.3%)	3	0/12 (0%)	0
Pruritus right forearm and both thighs	1/12 (8.3%)	1	0/12 (0%)	0
Surgical and medical procedures
Pain following dental surgery	0/12 (0%)	0	1/12 (8.3%)	1
Vascular disorders
Facial flushing	0/12 (0%)	0	1/12 (8.3%)	2
Worsening of hypertension	1/12 (8.3%)	1	0/12 (0%)	0

Limitations/Caveats

The lack of validated scales to specifically assess severity of palmoplantar psoriasis. The study was powered to detect a difference of 55 percentage points.

More Information

Certain Agreements

Principal Investigators are NOT employed by the organization sponsoring the study.

The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.